Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592720 | SCV000702610 | uncertain significance | not provided | 2018-05-29 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764467 | SCV000895532 | uncertain significance | Renal-hepatic-pancreatic dysplasia 1; Nephronophthisis 3; NPHP3-related Meckel-like syndrome | 2022-04-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001035032 | SCV001198339 | uncertain significance | Nephronophthisis | 2023-10-03 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 315 of the NPHP3 protein (p.Asp315Val). This variant is present in population databases (rs149565564, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with NPHP3-related conditions. ClinVar contains an entry for this variant (Variation ID: 497874). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NPHP3 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV000592720 | SCV002542073 | uncertain significance | not provided | 2021-09-07 | criteria provided, single submitter | clinical testing |